about
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experienceThe pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaTreatment of hepatic metastases from colorectal cancer: many doubts, some certainties.Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma.Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsPredicting treatment outcome in classical Hodgkin lymphoma: genomic advancesExtranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series.Bendamustine: role and evidence in lymphoma therapy, an overview.Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.Slow evolution of liver metastasis from colon cancer.Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission.Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease.
P50
Q33376304-02942E76-7EB0-4436-ADF1-3534E1E59C34Q33378233-41CF10B2-2AC4-43CA-86D0-E9D32E03882CQ33378775-CE7D4EB3-8C63-4479-8E2D-DAC5F7F7B9DBQ33390098-9C728053-E628-4844-9F7C-652F96E405FBQ33396803-43375306-4AB2-4577-BB3E-9C48979DE6FBQ33404090-CCC92DE8-3086-4CB9-BFF1-D22B22FB9804Q33829759-77C2B7E7-10D2-45DD-87D9-4A6D7031A762Q34648812-2DBE1904-8C75-4C8B-831C-142AEC6FDB2AQ35223868-D2066053-74F1-4B66-A81F-EA807EDB6511Q35664956-3AFC2D71-8527-4442-88FC-9D420A14E97DQ35836477-242F7F90-468E-43A5-BB4B-A5F0806013B2Q35953399-3294AFE9-BD94-4D03-8F74-0536BC11EC87Q36255484-FC7588C4-CDBB-49F8-B797-6B64EEA32B78Q36424876-421B952B-0AAD-4EB6-A7DA-CE08AEF94D9FQ37054491-8AAABFCF-0376-4263-A7B7-37AE297D8B4DQ37060652-37F5CC9F-60F3-42EC-AE50-DC98E655FC56Q37872044-0699EC54-7BD5-4531-A35E-47FCB8AECAAFQ38065131-1F7DB24E-67A9-4D90-BA3C-353ABD33B6C7Q38067963-BF872DA6-6BD5-44B9-BD64-3ECC4F22E613Q38158084-E21F41AE-27F1-4352-A67D-6225DFB03081Q42992750-9D2DBAB9-1DD4-4B40-9B8B-559626CC4EE0Q43165951-F954DEF1-4C0E-4404-929B-6D8BB286FC6FQ43249154-22FEF12C-4391-40C0-BE2E-4D712D9FF84DQ43253822-DEF858B8-14E1-45CF-A9D5-4AF1663EC527Q43257785-175EA049-3025-4276-8883-A0AC49E35E5DQ43265079-C31F50FA-A922-422F-BC26-A2A71BF7A586Q43457873-8FD4154E-27DB-4D3E-A029-CD421E07D193Q44798311-B143A0D7-CC19-4D34-9B38-FBB567CB4153Q45912397-9827BB95-74ED-4ACC-88BC-226993751B04Q46094228-F1976177-19E5-4D37-8175-FBBD0EAA6478Q46333356-2D63603F-9F9D-496A-BC26-89B9B4E95FE3Q46582399-CEBDB652-5C9D-4E92-BB23-E5DFCB329584Q46698290-F2BA51A1-6AF2-4D5C-B09B-5672D8BB8ADCQ46700738-EE94AA4F-9852-4EF6-85C8-5597E6B90B06Q46909222-D04D4E3F-6B9F-4555-95A0-DB6F3517E546Q47974824-F463E9A4-BC59-4A0F-AB52-0FE898DEACEDQ51039125-4FC9113E-5293-4458-A93B-72E80F9376E5Q51161624-28E5C73F-B0EA-4992-B78B-91140CD31715Q51646044-8415C9AA-6D8F-4FDD-AF95-AACC9734BE17Q53225891-D3C3D3DF-7A84-454D-A490-AF44BCC354BE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Enrico Derenzini
@ast
Enrico Derenzini
@en
Enrico Derenzini
@es
Enrico Derenzini
@nl
Enrico Derenzini
@sl
type
label
Enrico Derenzini
@ast
Enrico Derenzini
@en
Enrico Derenzini
@es
Enrico Derenzini
@nl
Enrico Derenzini
@sl
prefLabel
Enrico Derenzini
@ast
Enrico Derenzini
@en
Enrico Derenzini
@es
Enrico Derenzini
@nl
Enrico Derenzini
@sl
P106
P1153
22233756800
P21
P31
P496
0000-0002-7154-8140